In a recent study, screening for BCL2 G101V and D103Y in 67 relapsed/refractory CLL patients on venetoclax revealed their presence in 10.4% and 11.9% of the cases, respectively, with four patients harboring both resistance mutations. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.